Literature DB >> 8586466

The p53 gene and its role in human brain tumors.

O Bögler1, H J Huang, P Kleihues, W K Cavenee.   

Abstract

Mutation of the p53 gene is among the most common lesions in a variety of human tumors, including those of the central nervous system. In most instances, mutation of one p53 allele is followed by loss of the remaining wild-type allele, resulting in cells with a complete absence of functional wild-type p53 protein. However, in some situations, such as at initiation of spontaneously arising gliomas or as the germline configuration of patients with the Li-Fraumeni syndrome, cells clearly carry both wild-type and mutant p53 alleles. These observations lead to the hypothesis that p53 mutations can give rise to loss of tumor suppressor functions as well as to gain of oncogenic transformation capabilities. In this review, we define the types of mutations that occur in the p53 gene in various glial tumors, contrast that with the spectra described in other human tumor types, and discuss the biochemistry and physiology of the p53 protein and its ability to regulate and be regulated by other gene products. We use this information to propose roles for p53 in the initiation and progression of human gliomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8586466     DOI: 10.1002/glia.440150311

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  41 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells.

Authors:  Guilin Li; Renzhi Wang; Jun Gao; Kan Deng; Junji Wei; Yanping Wei
Journal:  Mol Cell Biochem       Date:  2010-12-24       Impact factor: 3.396

Review 3.  The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis.

Authors:  Chengya Dong; Zhengrong Yuan; Qi Li; Yajie Wang
Journal:  Neurol Sci       Date:  2018-04-12       Impact factor: 3.307

4.  Humoral immune response to p53 in malignant glioma.

Authors:  M Weller; A Bornemann; M Ständer; M Schabet; J Dichgans; R Meyermann
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

5.  TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Authors:  Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-02-07       Impact factor: 3.311

Review 6.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

Review 7.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

Authors:  Camilla Krakstad; Martha Chekenya
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

Review 8.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 9.  Angiogenesis factors in gliomas: a new key to tumour therapy?

Authors:  Rolf Mentlein; Janka Held-Feindt
Journal:  Naturwissenschaften       Date:  2003-07-29

10.  Senescence from glioma stem cell differentiation promotes tumor growth.

Authors:  Rie Ouchi; Sachiko Okabe; Toshiro Migita; Ichiro Nakano; Hiroyuki Seimiya
Journal:  Biochem Biophys Res Commun       Date:  2016-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.